Abstract
Simple SummaryPancreatic cancer has the worst survival of any human cancer. Checkpoint blockade has not yielded much benefit in pancreatic cancer. We explored immune cell phenotypes with this disease to identify new targets for checkpoint blockade therapy. We created a checkpoint-focused panel to analyse immune cells from eight pancreatic cancer patients. This showed us the majority of T-cells are senescent. Further T-cell investigation demonstrated the majority of cytotoxic T-cells have intermediate to low PD1 expression suggesting why PD1 may not work as a pancreatic cancer therapy strategy. Our data has also highlighted a regulatory T-cell population which is highly activated and can mediate immunosuppression. The checkpoints that are highly expressed on these cells are TIGIT, ICOS and CD39, suggesting inhibition of these may be a viable therapeutic strategy. Furthermore, we showed that Tregs were retained amongst the fibroblast stroma of the tumour. Our work suggests there are key checkpoints on Tregs that may help guide therapeutic strategies in pancreatic cancer.Pancreatic cancer has one of the worst prognoses of any human malignancy and leukocyte infiltration is a major prognostic marker of the disease. As current immunotherapies confer negligible survival benefits, there is a need to better characterise leukocytes in pancreatic cancer to identify better therapeutic strategies. In this study, we analysed 32 human pancreatic cancer patients from two independent cohorts. A multi-parameter mass-cytometry analysis was performed on 32,000 T-cells from eight patients. Single-cell RNA sequencing dataset analysis was performed on a cohort of 24 patients. Multiplex immunohistochemistry imaging and spatial analysis were performed to map immune infiltration into the tumour microenvironment. Regulatory T-cell populations demonstrated highly immunosuppressive states with high TIGIT, ICOS and CD39 expression. CD8+ T-cells were found to be either in senescence or an exhausted state. The exhausted CD8 T-cells had low PD-1 expression but high TIGIT and CD39 expression. These findings were corroborated in an independent pancreatic cancer single-cell RNA dataset. These data suggest that T-cells are major players in the suppressive microenvironment of pancreatic cancer. Our work identifies multiple novel therapeutic targets that should form the basis for rational design of a new generation of clinical trials in pancreatic ductal adenocarcinoma.
Highlights
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst outcomes of any human cancer with a 5-year survival of around 7% [1,2]
We identified 13 Treg clusters based on FOXP3 expression, all of which exhibit high expression levels of TIGIT and co-expressing ICOS and ENTPD-1 (CD39) (Figure 3B, violin plots, Supplemental Data File 1)
We identified 6 clusters of senescent T-cells (Figure 3C) characterised by increased NK marker expression (KLRG1, KLRB1) and senescent markers (HCST, HMGB1) [34], which were significantly elevated in the tumour samples compared to the normal pancreas (Figure S11C), suggesting this is a unique characteristic of the tumour microenvironment and is not solely a result of the age of the cohort
Summary
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst outcomes of any human cancer with a 5-year survival of around 7% [1,2]. We and others have shown that the immune infiltrate in the primary pancreatic tumour is prognostic of the clinical course after a surgical resection [4,5]. Checkpoint blockade immunotherapies, especially antibodies to PD-1 and PD-L1, reactivate tumour-specific T-cells and have demonstrably improved the prognosis of melanoma and lung cancer [11,12]. These immunotherapies have had minimal effects on outcomes in pancreatic cancer, with no durable responses in patients [13,14,15,16]. There is some suggestion that checkpoint therapy can be enhanced in pancreatic cancer by the additional of adjuncts such as oncolytic viruses [17]
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have